M&A / Deals Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal BioPharma DiveThe purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.Rare DiseaseRead full story pharminent July 1, 2026 (Last updated: July 1, 2026) BioPharma Dive The purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients. Rare Disease Read full story Post navigation Previous: AlzeCure enters collaboration agreement with QuantumCell ApS for NeuroRestore projectNext: Decoding Medicare Advantage Coding Intensity Related Stories M&A / Deals Boehringer signs AI drug discovery deal with Owkin pharminent September 3, 2026 M&A / Deals Novartis signs $3.2bn drug delivery deal with Alteogen pharminent September 3, 2026 M&A / Deals Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology pharminent September 2, 2026